低氧条件下重度冻伤家兔血凝系统某些因素的改变及其治疗的研究

血液循环障碍是重度冻伤组织坏死的主要原因 ,而冻后血液凝固性质的改变在血液循环障碍中起了十分重要的作用 ;研究表明低氧可以加重冻伤损伤程度。本研究对低氧条件下重度冻伤家兔血凝系统某些因素的改变进行了观察 ,并探讨了抗栓、溶栓、稀释血液等综合治疗措施对其治疗作用 ,以进一步阐明高原冻伤的发病机制、为其防治措施提供依据。1　材料与方法(1)实验动物与分组　实验采用体重 2 .5～ 3.0ｋｇ的健康雄性大耳白家兔 (军事医学科学院动物中心提供 ) ,动物单笼喂养 ,饲混合块料 ,随意饮水 ,室温 (2 0± 2 )℃ ,光照 12ｈ/ｄ ,饲养一周后…     

冻伤对大鼠血凝系统某些因素的影响

本研究观察了大鼠双后足局部冻伤后其血凝系统某些因素的改变。结果表明,冻伤后大鼠的出血时间及凝血时间明显缩短,血小板数增加,血小板聚集率增高,血浆血栓素Ａ２、纤维蛋白原及钙离子浓度均明显增加,且上述指标的改变与冻伤程度有密切关系,冻伤愈重,改变愈明显,恢复亦愈慢。结果提示,冻伤可使血凝系统发生改变,血液处于高凝状态,这对浆伤后发生的血液循环障碍最终导致冻伤组织坏死的病理过程起重要作用。     

不同蝮蛇抗栓酶对动物的神经毒性敏感反应

给小鼠、家兔、豚鼠等３种动物注射不同剂量的两种蝮蛇抗栓酶,观察它们的反应。结果：东北白眉蝮蛇抗栓酶未见神经毒反应,而浙江蝮蛇抗栓酶有神经毒反应,以豚鼠的反应最为敏感,主要表现为箭毒样毒性症状     

蝮蛇抗栓酶对实验性矽肺治疗作用的研究

本文报告了蝮蛇抗栓酶对大鼠实验性矽肺的治疗有很好的疗效。其治疗机理为：通过染尘大鼠肺干重及全肺胶原蛋白测定其Ｔ／Ｃ值分别为０．６８和０．７１,其病理切片以１级为主。提示蝮蛇抗栓酶有抑制肺纤维化的作用,延缓矽肺的进展;通过用ＴＢＡ反应萤光比色法测定肺组织中丙二醛（ＭＤＡ）含量,结果表明：蝮蛇抗栓酶能显著地降低肺组织中ＭＤＡ含量（Ｐ＜０．０１）。提示蝮蛇抗栓酶具有体内抗氧化作用,提高体内ＳＯＤ水平,促进体内抗脂质过氧化的作用。抑制和减慢了肺组织原纤维化过程,从而起到抗胶原反应的作用。同时对抗了矽尘对肺组织损伤作用;通过测定染尘大鼠血液流变学中全血高切和低切粘度比,血浆粘度比、红细胞聚集指数和血沉等指标,均高于正常对照组,说明矽肺存在高粘滞血症,用蝮蛇抗栓酶治疗后其五项指标与矽肺对照组比较有显著性差异（Ｐ＜０．０５）提示蝮蛇抗栓酶有效地改变血液中的高粘滞状态,改善微循环,使矽肺病情得以缓解。     

蝮蛇抗栓酶治疗脑动脉硬化记忆障碍患者48例疗效观察

对４８例脑动脉硬化记忆障碍患者进行蝮蛇抗栓酶治疗,并在治疗前后进行记忆力测定,结果治疗后记忆检查总分明显高于治疗前,证明蝮蛇抗栓酶有明显改善脑动脉硬化记忆障碍的作用     

蝮蛇抗栓酶治疗庆大霉素中毒

应用蝮蛇抗栓酶治疗庆大霉素中毒6例,其中1例由于合并严重神经症状及应用蝮蛇抗栓酶时间延长,需8个月治愈,余5例因应用蝮蛇抗栓酶及时,两周即治愈.总之,应用蝮蛇抗栓酶治疗6例庆大霉素中毒患者均获得理想效果。     

蝮蛇抗栓酶对家兔慢性胆囊炎防治的实验研究

作者用家兔４２只随机分成造型组（Ａ）,预防组（Ｂ）及治疗组（Ｃ）。各组又分处理组（Ａ１、Ｂ１、Ｃ１）和对照组（Ａ２、Ｂ２、Ｃ２）两个亚组。Ａ２组仅喂基本饲料,其余５组喂基本饲料加造型剂。Ａ组没用任何治疗。Ｂ１组慢性胆囊炎形成前,Ｃ１组慢性胆囊炎形成后分别用蝮蛇抗栓酶（０．２Ｕ／ｋｇ／日３０天）,Ｂ２和Ｃ２组仅给等量生理盐水。Ａ２及治疗后的Ｂ１、Ｃ１组血清胆固醇含量均明显低于Ａ１、Ｂ２、Ｃ２组（Ｐ＜０．０５）。胆囊的病理变化,Ｂ２和Ｃ２组改变明显,表面呈暗褐色,与周围组织粘连,粘膜面粗糙,胆囊壁增厚,体积增加,胆汁潴留,镜下粘膜增生呈乳头状,部分粘膜脱落,粘膜下及肌层水肿,炎细胞浸润。结果表明,蝮蛇抗栓酶对慢性胆囊炎既有预防作用又有治疗作用。     

蝮蛇抗栓酶治疗闭塞性脑血管病118例

蝮蛇抗栓酶治疗闭塞性脑血管病１１８例王亚利军委第二炮兵礼士路门诊部北京１００８２０我科１９９１年４月至１９９３年４月,经ＣＴ扫描确诊为脑血栓患者１１８例,应用“蝮蛇抗栓酶”（清栓酶）治疗,收到明显疗效,尤其对血液动力学的改变有明显促进作用。１资料和方...     

蝮蛇抗栓酶治疗急性心肌梗塞疗效与剂量,时间的关系

用蝮蛇抗栓酶治疗急性心肌梗塞６２例,按用药剂量及治疗时间各分成２组对比,结果表明在急性心肌梗塞早期（８ｈ内）使用大剂量蝮蛇抗栓酶（＞２ＩＵ）,治疗效果较明显且病死率明显降低（Ｐ＜０．０５）。     

蛇毒酶对帕金森氏病和帕金森综合征的治疗研究

目的研究观察蛇毒酶治疗帕金森氏病（ＰＤ）、帕金森综合征（ＰＳ）的临床效果,方法对８２例ＰＤ和ＰＳ患者进行随机分组,Ａ组应用精制蝮蛇抗栓酶,Ｂ组应用东菱克栓酶,Ｃ组应用力源精纯溶栓酶;对每例病人进行治疗前后Ｗｅｂｓｔｅｒ记分和记录多巴制剂的递减／递增量,同时检测血液流变学和血凝学５项指标,并给予统计比较,结果Ａ组病例不论是临床症状的改善,还是多巴制剂的用量递减、血液流变学和血凝学指标变化均优于Ｂ、Ｃ     

Acute systemic changes in blood cells, proteins, coagulation, fibrinolysis, and platelet aggregation after frostbite injury in the rabbit

Acute systemic blood changes were measured in New Zealand white rabbits after severe and mild frostbite injury to the foot. There were observed after 72 hr, in the severely frostbitten rabbits, a decrease in erythrocytes, hematocrit, lymphocytes, and albumin, and an increase in total leukocytes, neutrophils, platelets, fibrinogen, and antithrombin III. Mildly frostbitten rabbits showed similar changes except for no changes in the platelets, albumin, and antithrombin III. In severely frostbitten rabbits, after 72 hr, the changes in the plasma coagulation tests were a prolonged partial thromboplastin time, an accelerated prothrombin time, and increased activities of Factors VII, IX, X, and XI. In mildly frostbitten rabbits there were a prolonged partial thromboplastin time and an increased activity of Factor VII. No changes in fibrinolysis were seen in either group of rabbits. Platelet aggregation, studied only in the severely frostbitten rabbits, showed a change only by an increase in the slope of the collagen-induced platelet aggregation. The blood changes observed in the rabbit model are different than those reported in human frostbite cases. No disseminated intravascular coagulation was apparent in the rabbit model after frostbite injury.     

回生口服液对晚期非小细胞肺癌患者血浆纤维蛋白原和 血小板水平的影响

目的：研究回生口服液对晚期非小细胞肺癌患者血浆纤维蛋白原和血小板水平的影响。方法：选取2011 年1 月至2013 年7 月已被收治的112 例晚期非小细胞肺癌患者按照知情同意原则随机分为治疗组（60 例）和对照组（52 例）两组,治疗组在支持、对 症治疗的基础上口服回生口服液治疗,对照组仅给予支持、对症治疗,4 周后观察两组患者经两种不同的治疗方案治疗后患者血 浆纤维蛋白原及血小板水平变化。结果：治疗组经给药治疗后血浆纤维蛋白原及血小板水平与治疗前相近,差异均无统计学意义 （P>0.05）;对照组经治疗后血浆纤维蛋白原及血小板水平较治疗前高,差异均有统计学意义（P<0.05）;治疗组给药治疗后血浆纤 维蛋白原及血小板水平均较对照组低,差异均有统计学意义（P<0.05）。结论：回生口服液可能是通过降低血浆纤维蛋白原及血小 板的含量从而改善晚期非小细胞肺癌患者的血液高凝状态。     

Blood viscosity parameter correlation with types of leukemia.

We investigated the hemorheological, hematological and biochemical parameters in 30 cases of acute lymphocytic leukemia (ALL), 21 cases of acute myelogenous leukemia (AML) and 30 cases of chronic myelogenous leukemia (CML). The parameters studied include whole blood viscosity, plasma viscosity, erythrocyte sedimentation rate (ESR), red cell filterability, hematocrit, platelet count and aggregation, fibrinogen, hemoglobin, leucocyte count, bleeding time and lactate dehydrogenase activity (LDH). In the cases of ALL we observed significant decrease in whole blood viscosity, hemoglobin, hematocrit and platelet count but an increase in plasma viscosity, fibrinogen, bleeding time and LDH activity. In the cases of AML, we observed increase in whole blood viscosity, plasma viscosity, ESR, fibrinogen, leucocyte count, bleeding time and LDH activity but decrease in the hemoglobin, hematocrit and platelet count. In the cases of CML, we observed an increase of whole blood viscosity, plasma viscosity, ESR, fibrinogen elevation but decreases in bleeding time. In all cases, red cell filterability was unaffected.     

缺氧对冻伤兔足皮肤温度和肌糖元含量的影响

采用测定冻伤兔足皮肤温度和肌糖元含量的方法,间接观察在缺氧条件下兔足重度冻伤血液循环和肌肉能量代谢的改变。实验结果表明：平原冻伤组、急性缺氧冻伤组、缺氧两周冻伤组冻足皮肤温度和肌糖元含量均明显降低。经４０℃０．１％的洗必泰液多次温浸治疗冻伤兔足,平原冻伤组和急性缺氧冻伤组的治疗足皮肤温度和肌糖元含量均高于未治疗足,无明显差异,提示在此种条件下冻足的血液循环障碍可能更加严重。     

回生口服液对晚期非小细胞肺癌患者血浆纤维蛋白原和血小板水平的影响

目的：研究回生口服液对晚期非小细胞肺癌患者血浆纤维蛋白原和血小板水平的影响。方法：选取2011年1月至2013年7月已被收治的112例晚期非小细胞肺癌患者按照知情同意原则随机分为治疗组（60例）和对照组（52例）两组,治疗组在支持、对症治疗的基础上口服回生口服液治疗,对照组仅给予支持、对症治疗,4周后观察两组患者经两种不同的治疗方案治疗后患者血浆纤维蛋白原及血小板水平变化。结果：治疗组经给药治疗后血浆纤维蛋白原及血小板水平与治疗前相近,差异均无统计学意义（P〉0．05）;对照组经治疗后血浆纤维蛋白原及血小板水平较治疗前高,差异均有统计学意义（P〈0．05）;治疗组给药治疗后血浆纤维蛋白原及血小板水平均较对照组低,差异均有统计学意义（P〈0．05）。结论：回生口服液可能是通过降低血浆纤维蛋白原及血小板的含量从而改善晚期非小细胞肺癌患者的血液高凝状态。     

Blood coagulation and immunological changes associated with frostbite at high altitude

In 15 cases of frostbite among soldiers stationed between 3690 and 5540 m altitude in the Himalayas investigations of blood coagulation and immunoglobulins were carried out within 24 hours, after 4 weeks and one year. In frostbite evidences of intravascular coagulation were the presence of increased amounts of FDPs in serum, reduction of plasma fibrinogen, fall in platelet counts and haematocrit, increased platelet adhesiveness, and prolonged euglobulin lysis time. Marked lowering of antithrombin III and protease inhibitors -1 antitrypsin and 2 macroglobulin indicate their increased consumption in the pathological process. Increased immunolglobulins with relative decrease of albumin and the appearance of cryoglobulins in the form of IgG, IgA and IgM complexes, also seem to promote platelet aggregation and release reaction. Anticoagulant therapy combined with antiplatelet adhesive drugs, if instituted in the early stages of frostbite might be successful in preventing damage resulting from intravascular coagulation.     

"U"字缝合止血法对前置胎盘剖宫产患者术中出血量的影响

目的:探讨"U"字缝合止血法对前置胎盘剖宫产患者术中出血量的影响。方法:将2015年9月至2017年9月在西北妇女院儿童医院行前置胎盘剖宫产术的产妇96例作为研究对象,将其随机分组为两组,每组各48例患者。两组均给予常规止血处理,对照组采用"8"字缝合止血法,观察组为"U"字缝合止血法,比较两组手术指标及止血效果。结果:观察组手术时间、止血时间、术中出血量均显著少(短)于对照组(P0.05),凝血酶时间(TT)、血浆凝血酶还原时间(PT)、D-二聚体(D-D)、血小板(PLT)以及活化部分凝血活化酶时间(APTT)水平均明显低于对照组(P0.05),血红蛋白(HGB)、纤维蛋白原(FIB)水平均显著高于对照组(P0.05);止血有效率[97.92%(47/48)]显著高于对照组[85.42%(41/48)](P0.05),患者下床活动时间、住院治疗时间均显著短于对照组(P0.05)。结论:在前置胎盘剖宫产术中,实施"U"字缝合止血法可快速止血,且操作简单,确保降低出血量,降低对患者的损害,保证产妇健康和安全。     

精纯抗栓酶治疗急性脑梗死的临床观察

目的 观察精纯抗栓酶治疗急性脑梗死的临床疗效。方法 １５６例经临床和头颅ＣＴ确诊的急性脑梗死患者,随机分为治疗组（８０例）和对照组（７６例）。对照组应用低分子右旋糖酐５００ｍｌ加复方丹参２０ｍｌ静滴,每天１次,连用１４天。治疗组在对照组治疗基础上,辅予应用精纯抗栓酶。两组均于治疗前后观察血液流变学、血小板计数及出、凝血时间。并于治疗前和治疗后２１天作神经功能评分,结合治疗后患者病残程度评定疗效。结     

Disseminated intravascular coagulation following intravenous Corynebacterium parvum injection in the rat

Summary Corynebacterium parvum (C. parvum) was administered by a single IV injection (14 mg/kg) to rats, and platelet counts, plasma fibrinogen concentrations and thrombin clotting times were monitored for up to 7 weeks. During this time histological and ultrastructural studies were also conducted. Thrombocytopoenia, hypofibrinogenaemia, and prolongation of the thrombin clotting time rapidly followed C. parvum injection and were accompanied by the appearance of platelet clumps and fibrin within blood vessels in a variety of tissues. This initial episode of disseminated intravascular coagulation (DIC) subsided 12–24 h after injection, but a more prolonged second episode of DIC occurred 1–3 days after injection. The results suggest that caution should be observed when systemic immunotherapy with C. parvum is proposed.